



BLA 125427/S-087

**SUPPLEMENT APPROVAL**

Genentech, Inc.  
Attention: Monica Shah  
Regulatory Program Management  
1 DNA Way, MS# 241B  
South San Francisco, CA 94080-4990

Dear Ms. Shah:

Please refer to your Supplemental Biologics License Application (sBLA), dated December 19, 2014, received December 19, 2014, submitted under section 351(a) of the Public Health Service Act for Kadcyła<sup>®</sup> (ado-trastuzumab emtansine), sterile lyophilized single use vial, 100 mg and 160 mg vials (20 mg/mL).

We acknowledge receipt of your amendment dated April 22, 2015.

This "Prior Approval" supplemental biologics application proposes the following changes:

1. Update to the US package insert (USPI) to reflect a change in the Kadcyła<sup>®</sup> (ado-trastuzumab emtansine) washout period recommendation from 6 to 7 months, supported by Herceptin's labeling update based on the popPK model.
2. Update the Dosage and Administration section, preparation for administration sub-section within the USPI to include the option of a 0.2 $\mu$  filter.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision listed below:

1. Section 17 (4<sup>th</sup> bullet) subsection # 8.6 in *Use in Specific Populations (8.1, 8.6)* was inadvertently left out in the finalized package insert and has been added back in.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling

[21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Rajesh Venugopal, Regulatory Project Manager, at (301) 796-4730.

Sincerely,  
*{See appended electronic signature page}*

Amna Ibrahim, MD  
Deputy Director  
Division of Oncology Products 1  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

AMNA IBRAHIM  
05/29/2015